Loading…
Capricor Therapeutics, Inc. is projected to rise to $26.34 by 2027, a +22% move from its current price of $21.51. CAPR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $20.73 | $21.51 | $22.32 | 0.00% |
| Jul 14 | $20.41 | $21.51 | $22.67 | 0.00% |
| Jul 15 | $20.17 | $21.51 | $22.94 | 0.00% |
| Jul 16 | $19.97 | $21.51 | $23.17 | 0.00% |
| Jul 17 | $19.80 | $21.51 | $23.37 | 0.00% |
| Jul 18 | $19.64 | $21.51 | $23.55 | 0.00% |
| Jul 19 | $19.50 | $21.51 | $23.73 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.50 | $21.51 | $23.73 | -0.01% |
| Week 2 | $18.72 | $21.51 | $24.71 | -0.01% |
| Week 3 | $18.15 | $21.51 | $25.49 | -0.02% |
| Week 4 | $17.67 | $21.51 | $26.17 | -0.02% |
| Week 5 | $17.27 | $21.50 | $26.78 | -0.03% |
| Week 6 | $16.91 | $21.50 | $27.34 | -0.03% |
| Week 7 | $16.59 | $21.50 | $27.87 | -0.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Its lead product candidate is Deramiocel, an allogeneic cardiosphere-derived cells, in phase 3 clinical trial for the treatment of DMD. The company also develops an Exosome protein-based vaccine in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and an exosome platform program consisting of engineered exosomes for vaccine and therapeutic development, which is in preclinical trial. It is pursuing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
The company holds license agreements with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services, along with a nonexclusive right to the know-how; It also has a Cell Line License Agreement with Life Technologies for the development of the exosome platform. The company was founded in 2005 and is headquartered in San Diego, California.
Capricor Therapeutics, Inc. (CAPR) is a healthcare stock currently priced at $21.51. It carries a market capitalization of $1.25B and holds a rank of 2382 by market cap.
The forecast horizon from 2026 to 2050 shows the average price trending higher, with 2026 at $21.51 and 2050 averaging $120.32, driven by a projected maximum of $252.07 in 2050 and a long-run bullish stance. The annualized outlook includes a progression in average prices and growing ROI, culminating in a 2050 ROI of 459.4. Overall sentiment shifts toward bullish in the later years.
A major floor 27.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 41.3% above — a clean break opens room to run.
A major ceiling 64.3% above — clearing it would confirm fresh momentum.
Key CAPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CAPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.18 | Sell | $22.35 | Sell |
| MA 10 | $23.15 | Sell | $23.39 | Sell |
| MA 20 | $25.51 | Sell | $24.86 | Sell |
| MA 50 | $28.01 | Sell | $27.04 | Sell |
| MA 100 | $29.35 | Sell | $27.01 | Sell |
| MA 200 | $22.69 | Sell | $23.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.82 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -106.63 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.39 | Sell |
| ROC (12) | -27.33 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.69 | Sell |
| Awesome (5,34) | -4.35 | Sell |
| Ultimate (7,14,28) | 18.02 | Buy |
| Momentum (10) | -8.89 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 21.73 | Sell |
| ADX (14) | 24.67 | Sell |
| ATR (14) | 0.82 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 30, indicating modest near-term momentum.
The 50-day simple moving average stands at $28.01, while the 200-day simple moving average sits at $22.69, suggesting a mix of technical supports and resistance nearby. The price currently shows support at $21.51 and resistance at $30.40, framing a breakout window beyond the immediate range.
In the most recent 30-day window, the price has traded between $16.85 and $27.47, reflecting a relatively wide swing for a still-volatile equity within its sector.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $21.51 | $21.51 | $29.07 | 0% | Neutral | |
| $20.27 | $26.34 | $36.59 | +22% | Bullish | |
| $21.80 | $29.46 | $42.93 | +37% | Bullish | |
| $18.89 | $26.39 | $39.91 | +23% | Bullish | |
| $19.78 | $28.46 | $44.40 | +32% | Bullish | |
| $22.67 | $33.50 | $53.68 | +56% | Bullish | |
| $26.05 | $39.50 | $64.82 | +84% | Bullish | |
| $29.97 | $46.54 | $78.03 | +116% | Bullish | |
| $28.93 | $45.98 | $78.63 | +114% | Bullish | |
| $28.06 | $45.59 | $79.40 | +112% | Bullish | |
| $41.06 | $73.92 | $138.91 | +244% | Bullish | |
| $55.46 | $120.32 | $252.07 | +459% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $21.51 | $21.51 | $26.63 | +0.00% |
| August 2026 | $18.26 | $21.76 | $26.79 | +1.17% |
| September 2026 | $17.86 | $21.49 | $26.85 | -1.23% |
| October 2026 | $18.46 | $22.40 | $28.33 | +4.19% |
| November 2026 | $18.69 | $22.84 | $29.19 | +1.97% |
| December 2026 | $18.32 | $22.53 | $29.07 | -1.34% |
Click any year to see its month-by-month CAPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CAPR price prediction for 2026 points to an average of $21.51 (low $21.51, high $29.07) — a potential gain of 0% on today's $21.51. A consolidation phase looks the most probable path here.
In 2027, CAPR is projected to trade between $20.27 and $36.59, averaging $26.34 — a potential gain of +22% from today's $21.51. That is up +22% on the projected 2026 average. Momentum favours further upside here.
Capricor Therapeutics, Inc.'s 2028 outlook centres on $29.46, within a $21.80 to $42.93 range. That is up +12% on the projected 2027 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CAPR could reach as high as $39.91, with a base case around $26.39 and support toward $18.89 — roughly +23% from $21.51. Momentum favours further upside here.
Expect CAPR to range from $19.78 to $44.40 through 2030. The $28.46 average target implies a +32% move from current prices. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CAPR price prediction for 2031 points to an average of $33.50 (low $22.67, high $53.68) — a potential gain of +56% on today's $21.51. Momentum favours further upside here.
In 2032, CAPR is projected to trade between $26.05 and $64.82, averaging $39.50 — a potential gain of +84% from today's $21.51. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Capricor Therapeutics, Inc.'s 2033 outlook centres on $46.54, within a $29.97 to $78.03 range. That is up +18% on the projected 2032 average. That marks a +116% change versus current levels. Momentum favours further upside here.
By 2034, CAPR could reach as high as $78.63, with a base case around $45.98 and support toward $28.93 — roughly +114% from $21.51. Buyers look set to stay in control over this stretch.
Expect CAPR to range from $28.06 to $79.40 through 2035. The $45.59 average target implies a +112% move from current prices. That is -1% versus the projected 2034 average. Momentum favours further upside here.
The CAPR price prediction for 2040 points to an average of $73.92 (low $41.06, high $138.91) — a potential gain of +244% on today's $21.51. Buyers look set to stay in control over this stretch.
In 2050, CAPR is projected to trade between $55.46 and $252.07, averaging $120.32 — a potential gain of +459% from today's $21.51. That is up +63% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CAPR today (≈ 46.490005 CAPR) could be worth
$5,593.56
+$4,593.56 (+459%) by 2050 · US Dollar
Based on the average projected CAPR price of $120.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CAPRwould be worth at today's price.
$1,000 invested in CAPR on Jul 10, 2025 (≈ 87.719301 CAPR) would be worth
$1,886.84
+$886.84 (+88.7%) today · 1.89× · US Dollar
Based on a CAPR entry price of $11.4 vs. today's $21.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.21 | $926.76 | -7.3% |
| 1 month ago | $25.33 | $849.19 | -15.1% |
| 3 months ago | $31.2 | $689.42 | -31.1% |
| 6 months ago | $24.51 | $877.6 | -12.2% |
| 1 year ago | $11.4 | $1,886.84 | +88.7% |
| All time (5.0y) ago | $4.59 | $4,686.27 | +368.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CAPR forecast.
Our base-case forecast reaches $43.00 around 2033.
Implied market cap at $43.00: $2.49B
The multi-year forecast paints a bullish path for Capricor, with meaningful upside across the horizon. In 2027, the expected average price is $26.34, rising from 2026’s level and continuing higher through subsequent years. The forecast for 2028 shows an average of $29.46, and the 2030 target sits at $28.46, reflecting a constructive longer-term trajectory alongside a rising sentiment.
By 2031 the average is projected at $33.50 and by 2032 at $39.50, with further gains to $46.54 in 2033, $45.98 in 2034, and $45.59 in 2035. The late-2030s and 2040s bring stronger upside, with 2040 averaging $73.92 and 2050 averaging $120.32, underscoring a substantial long-run growth path. ROI follows suit, reaching 32.3% in 2030, increasing to 243.7% in 2040 and 459.4% in 2050, with bullish sentiment through the horizon.
These are estimates and not guarantees; actual performance will depend on various factors. The forecast depicts a bullish bias over time, but investors should consider the inherent uncertainty in long-range price projections and the specific risks tied to biotech development and regulatory outcomes.
Tap a question to reveal the answer.
min $19.78, avg $28.46, max $44.40, ROI: 32.3, sentiment BULLISH.
The forecast shows a bullish trajectory in many later years (e.g., 2027–2035 and into 2040–2050) with rising averages, though 2026 is neutral with avg $21.51 and ROI 0. The long-run outlook indicates meaningful upside but carries typical biotech investment risks.
Yes. The 2050 forecast shows an average of $120.32, which would exceed $100 (2040’s average is $73.92, below $100).
low $16.85, high $27.47.
Capricor Therapeutics, Inc. Community Discussion
0Share your Capricor Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.